Ross Brewer Joins AttackIQ as a Strategic Advisor Focused on EMEA
AttackIQⓇ, the leading independent vendor of breach and attack simulation solutions, today announced the addition of Ross Brewer as strategic advisor of Europe, Middle East and Africa (EMEA). Bringing over 30 years of experience in cybersecurity to his new role, Brewer will focus on strengthening AttackIQ’s customer base in EMEA through strategic sales, marketing and other key growth initiatives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200421005209/en/
Ross Brewer, Strategic Advisor Focused on EMEA (Photo: Business Wire)
“We’ve made several strategic additions to our team in recent months as demand for our platform grows, and Ross is no exception,” said Carl Wright, chief commercial officer of AttackIQ. “We’ve been able to attract incredibly experienced, skilled cybersecurity professionals like Ross because in his career, he has witnessed over and over again companies struggling to effectively deploy security controls and ensure cyber readiness. Ross believes strongly in our vision and mission of making the world a safer place to compute.”
Brewer previously served as the vice president and managing director of EMEA for LogRhythm, a position he held for 12 years, and vice president and managing director of EMEA for LogLogic. In his time with LogRhythm, Brewer helped grow the company globally from around 25 employees to over 600, with more than 100 in EMEA alone. He also oversaw the opening of the majority of their international offices.
“I’ve made it my goal to help organizations think differently about how they utilize IT assets and resources to combat today’s rapidly evolving cyberthreats,” said Brewer. “Organizations must take an informed, unified approach to maturing their security operations with the right people, processes, technologies and partnerships, and AttackIQ empowers companies to do exactly that. I look forward to helping customers leverage this platform and the MITRE ATT&CK framework to ensure cyber readiness from an adversarial perspective.”
About AttackIQ
AttackIQ built the industry’s first platform that enables red and blue teams to test and measure the effectiveness of their security controls and staff. With an open platform, AttackIQ supports the MITRE ATT&CK framework, a curated knowledge base and model for cyber adversary behavior used for planning security improvements and verifying defenses work as expected. For more information visit http://www.attackiq.com/. Follow AttackIQ on Twitter, Facebook, LinkedIn, Vimeo, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005209/en/
Contact information
Emily Ashley
PR for AttackIQ
attackiq@10fold.com
916-710-0950
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton29.8.2025 07:35:00 EEST | Press release
The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/ “It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance. TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of r
Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom